In Brief: Neoprobe RIGScan CR49
This article was originally published in The Gray Sheet
Neoprobe RIGScan CR49: Firm plans to submit additional clinical and manufacturing information requested by FDA as an amendment to its existing biologics license application "as soon as possible." Neoprobe submitted a BLA in December 1996 for the radioimmuno-guided surgery system for detection of metastatic colon cancer ("The Gray Sheet" July 21, I&W-5). The RIGScan CR49 system consists of I125 labeled Colorectal 49 monoclonal mouse antibody and the Neoprobe 1000 radiation detection probe. Neoprobe President David Bupp notes the firm intends "to meet with the FDA at our earliest opportunity to determine the scope of the information requests"...
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.